OKAY
833230
CHANGFU CO.,LTD
871396
Gansu Longshenrongfa Pharmaceutical Industry
300534
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
US Stock MarketDetailed Quotes
LITE Lumentum
- 63.590
- +1.250+2.01%
Close Apr 1 16:00 ET
- 63.250
- -0.340-0.53%
Post 19:37 ET
4.40BMarket Cap-8.24P/E (TTM)
63.910High59.830Low3.60MVolume62.030Open62.340Pre Close225.70MTurnover5.56%Turnover RatioLossP/E (Static)69.20MShares104.00052wk High5.04P/B4.12BFloat Cap38.28552wk Low--Dividend TTM64.78MShs Float112.080Historical High--Div YieldTTM6.55%Amplitude13.970Historical Low62.653Avg Price1Lot Size
Lumentum Key Stats
Quarterly+Annual
YOY
| (Q2)Dec 28, 2024 | (Q1)Sep 28, 2024 | (FY)Jun 29, 2024 | (Q4)Jun 29, 2024 | (Q3)Mar 30, 2024 | (Q2)Dec 28, 2023 | (Q1)Sep 28, 2023 | (FY)Jul 1, 2023 | (Q4)Jul 1, 2023 | (Q3)Apr 1, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 9.65%402.2M | 6.08%336.9M | -23.08%1.36B | -16.86%308.3M | -4.41%366.5M | -27.51%366.8M | -37.33%317.6M | 3.18%1.77B | -12.15%370.8M | 383.4M |
| Operating revenue | 9.65%402.2M | 6.08%336.9M | -23.08%1.36B | -16.86%308.3M | -4.41%366.5M | -27.51%366.8M | -37.33%317.6M | 3.18%1.77B | -12.15%370.8M | --383.4M |
| Cost of revenue | -0.07%302.6M | 7.51%259M | -7.54%1.11B | -8.61%257M | 13.12%307M | -10.89%302.8M | -21.17%240.9M | 29.65%1.2B | 16.97%281.2M | 271.4M |
| Gross profit | 55.63%99.6M | 1.56%77.9M | -55.80%251.5M | -42.75%51.3M | -46.88%59.5M | -61.49%64M | -61.88%76.7M | -27.85%569M | -50.69%89.6M | 112M |
| Operating expense | -7.89%150.5M | 2.80%150.6M | -6.66%612.9M | 4.15%148.1M | -4.26%154.9M | -6.20%163.4M | -17.88%146.5M | 34.99%656.6M | 12.59%142.2M | 161.8M |
| Selling and administrative expenses | -10.34%76.3M | 4.52%76.3M | -10.92%310.7M | 9.66%74.9M | 1.70%77.7M | -13.52%85.1M | -30.94%73M | 31.28%348.8M | -1.87%68.3M | --76.4M |
| Research and development costs | -5.24%74.2M | 1.09%74.3M | -1.82%302.2M | -0.95%73.2M | -9.60%77.2M | 3.30%78.3M | 1.10%73.5M | 39.47%307.8M | 30.34%73.9M | --85.4M |
| Operating profit | 48.79%-50.9M | -4.15%-72.7M | -312.56%-361.4M | -84.03%-96.8M | -91.57%-95.4M | -1,142.50%-99.4M | -406.14%-69.8M | -128.99%-87.6M | -194.95%-52.6M | -49.8M |
| Net non-operating interest income expense | -54.05%3.4M | -67.50%3.9M | 418.87%27.5M | -35.71%4.5M | 12.50%3.6M | 716.67%7.4M | 424.32%12M | 107.15%5.3M | 130.84%7M | 3.2M |
| Non-operating interest income | -47.37%9M | -56.68%9.4M | 50.25%61.3M | -39.63%9.9M | 5.88%12.6M | 122.08%17.1M | 352.08%21.7M | 568.85%40.8M | 331.58%16.4M | --11.9M |
| Non-operating interest expense | -42.27%5.6M | -43.30%5.5M | -4.79%33.8M | -42.55%5.4M | 3.45%9M | 8.99%9.7M | 14.12%9.7M | -55.74%35.5M | -64.53%9.4M | --8.7M |
| Other net income (expense) | 154.74%5.2M | 9.57%-10.4M | -257.21%-71.8M | -17,750.00%-35.3M | -609.09%-15.6M | 47.22%-9.5M | -3,733.33%-11.5M | -387.14%-20.1M | -95.45%200K | -2.2M |
| Gain on sale of security | 259.46%5.9M | -40.00%-700K | -88.57%800K | -50.00%1.3M | 840.00%3.7M | 9.76%-3.7M | -105.56%-500K | 14.75%7M | -40.91%2.6M | ---500K |
| Special income (charges) | 87.93%-700K | 11.82%-9.7M | -158.36%-72.6M | -1,009.09%-36.6M | -1,100.00%-19.2M | 58.27%-5.8M | -18.28%-11M | -2,654.55%-28.1M | ---3.3M | ---1.6M |
| -Less：Restructuring and merger&acquisition | -87.93%700K | -11.82%9.7M | 158.36%72.6M | 1,009.09%36.6M | 1,100.00%19.2M | -58.27%5.8M | 18.28%11M | 2,654.55%28.1M | --3.3M | --1.6M |
| Other non- operating income (expenses) | ---- | ---- | ---- | ---- | 0.00%-100K | ---- | ---- | 600.00%1M | --900K | ---100K |
| Income before tax | 58.33%-42.3M | -14.29%-79.2M | -296.19%-405.7M | -180.84%-127.5M | -120.53%-107.4M | -274.54%-101.5M | -468.62%-69.3M | -143.56%-102.4M | -222.37%-45.4M | -48.7M |
| Income tax | 875.00%18.6M | 328.57%3.2M | 382.19%140.8M | 744.59%125M | 308.51%19.6M | -152.17%-2.4M | -107.29%-1.4M | -19.34%29.2M | 516.67%14.8M | -9.4M |
| Net income | 38.55%-60.9M | -21.35%-82.4M | -315.27%-546.5M | -319.44%-252.5M | -223.16%-127M | -212.62%-99.1M | -16,875.00%-67.9M | -166.16%-131.6M | -273.49%-60.2M | -39.3M |
| Net income continuous Operations | 38.55%-60.9M | -21.35%-82.4M | -315.27%-546.5M | -319.44%-252.5M | -223.16%-127M | -212.62%-99.1M | -16,875.00%-67.9M | -166.16%-131.6M | -273.49%-60.2M | ---39.3M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 38.55%-60.9M | -21.35%-82.4M | -315.27%-546.5M | -319.44%-252.5M | -223.16%-127M | -212.62%-99.1M | -16,875.00%-67.9M | -166.16%-131.6M | -273.49%-60.2M | -39.3M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | 38.55%-60.9M | -21.35%-82.4M | -315.27%-546.5M | -319.44%-252.5M | -223.16%-127M | -212.62%-99.1M | -16,875.00%-67.9M | -166.16%-131.6M | -273.49%-60.2M | -39.3M |
| Basic earnings per share | 40.14%-0.88 | -18.63%-1.21 | -320.73%-8.12 | -322.73%-3.72 | -229.82%-1.88 | -219.57%-1.47 | -10,100.00%-1.02 | -169.18%-1.93 | -276.00%-0.88 | -0.57 |
| Diluted earnings per share | 40.14%-0.88 | -18.63%-1.21 | -320.73%-8.12 | -322.73%-3.72 | -229.82%-1.88 | -219.57%-1.47 | -10,100.00%-1.02 | -172.01%-1.93 | -279.59%-0.88 | -0.57 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- |
Market Insights
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025